The new combination therapy can make the treatment response rate of the elderly patients with high-risk acute lymphoblastic leukemia reach 98%!

December 12, 2019 / Biovalley BIOON / -- recently, scientists from MD Anderson Cancer Research Center of the University of Texas found that the combination of low-dose chemotherapy and monoclonal antibody - Indo, inotuzumab ozogamicin (combined or not) may be safe and effective in the treatment of new diagnosis over 60 years old This type of leukemia is also called Philadelphia chromosome negative all Photo source: Nicholas, researcher, wikidoc.org Short said that when combined with iNO, reducing the intensity of chemotherapy can make the response rate of patients reach 98%, and the 3-year survival rate can also be increased to 54%; 95% of patients who respond to the treatment do not have minor residual diseases, which is crucial for the end-point of all treatment, and it is also related to the reduction of the risk of disease recurrence and the prolongation of survival period United Previously, researchers pointed out that when treating malignant all, the single dose effect of bonavomab and ino is more effective than the standard chemotherapy Now it may be a first-line treatment option Philadelphia chromosome negative all elderly patients often have very poor prognosis In previous studies, researchers found that the survival rate of such patients is often poor Less than 20%, which may be due to high-risk disease characteristics and poor chemotherapy tolerance In this study, the researchers treated 64 patients with an average age of 68, 98% (58) of 59 evaluable patients achieved full response to the treatment, and the overall 3-year survival rate of these patients reached 54% in the following 37 months of follow-up Among them, 30 patients showed complete remission without signs of minor residual diseases Short said that patients who received or did not receive bornetuzumab had similar outcomes, although more follow-up studies were needed to determine whether additional bornetuzumab would improve the long-term prognosis of patients The study conducted by the researchers significantly improved the 3-year survival rate of patients, while in similar historical cohort studies, the results were similar The 3-year survival rate of the elderly patients receiving intensive chemotherapy is only 32% The relevant research results are expected to improve the clinical treatment standard of the elderly patients with all Original source: combination therapy results in 98% response rate for some newly diagnosed leukemia patients a study led by the University of Texas MD Anderson Cancer Center showed that treatment combining lower does of chemotherapy with the monoclonal antibody inotuzumab ozogamicin (iNO), with or without the drug Bluetooth, is safe and effective in patients over 60 years of age who were newly diagnosed with a high-risk form of acute lymphoblastic leukemia (ALL) known as Philadelphia chromosome-negative ALL Findings from the study were presented by Nicholas Short, M.D., assistant professor of Leukemia, Dec 9 at the 61st American Society of Hematology Annual Meeting & Exposition in Orlando, Fla The study was led by Elias Jabbour, M.D., professor of Leukemia.......